Cargando…
Phase I study of pucotenlimab (HX008), an anti-PD-1 antibody, for patients with advanced solid tumors
BACKGROUND: Pucotenlimab is a humanized immunoglobulin G4 (IgG4) anti programmed cell death protein 1 (anti-PD-1) monoclonal antibody (mAb) with a S228P hinge mutation and an engineered Fc domain. Preclinical data suggests that pucotenlimab exerts antitumor effects. In this phase I study, which was...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8182631/ https://www.ncbi.nlm.nih.gov/pubmed/34158838 http://dx.doi.org/10.1177/17588359211020528 |